Document Type
Presentation
Loading...
Media is loading
Publication Date
3-14-2012
Abstract
Overall Goals and Objectives
1. Identify transdifferentiation as an important source of activated myofibroblasts in SSc and related fibrotic conditions.
2. Understand the implications of this phenomenon in lung fibrosis models.
3. Identify this phenomenon as possible target for future therapy for lung fibrotic diseases.
Presentation: 59 minutes
Recommended Citation
Mendoza, MD, Fabian A., "Role of the Endothelial-Mesenchymal Transdifferentiation in Pulmonary Fibrosis and Related Fibrotic Processes" (2012). Division of Pulmonary and Critical Care Medicine Presentations and Grand Rounds. Presentation 46.
https://jdc.jefferson.edu/pulmcritcaregrandrounds/46
COinS
Comments
Dr. Fabian Mendoza is an Assistant Professor of Medicine in the Division of Rheumatology at Thomas Jefferson University since 2009. Dr. Mendoza completed his rheumatology fellowship at Columbia University Medical Center (NY Presbyterian Hospital).
Current projects and grants:
Proposal for the evaluation of Nilotinib in diffuse Systemic Sclerosis of recent onset and rapid progression (phase II multicentric study) Co-PI Approved (multi-project NIH U19 Cooperative Agreement award mechanism).
Endothelial-mesenchymal transdifferentiation in Scleroderma lung disease. PI.
Pilot study of MicroRNA in Multiple Sclerosis and Systemic Sclerosis.
Muscarinic receptor activation trigger by Immunoglobulins from scleroderma patients (Collaboration project with DiMarino et al)